Minimal residual disease in acute lymphoblastic leukemia.

  title={Minimal residual disease in acute lymphoblastic leukemia.},
  author={Dario Campana},
  journal={Hematology. American Society of Hematology. Education Program},
In patients with acute lymphoblastic leukemia (ALL), treatment response is increasingly evaluated with minimal residual disease (MRD) assays. ALL cells can be recognized by their clonal rearrangement of immunoglobulin and T-cell receptor genes, expression of gene fusions, and leukemia-associated immunophenotypes. Assays based on polymerase chain reaction or flow cytometry can detect one ALL cell among 10,000 to 100,000 normal cells in clinical samples. The vast majority of cases have antigen… CONTINUE READING
160 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 160 extracted citations

Similar Papers

Loading similar papers…